If you’ve been watching the biotech sector lately, you know it’s basically been a rollercoaster with no seatbelts. Specifically, if you're tracking SRPT news today live, you’re seeing a company at a massive crossroads. Sarepta Therapeutics (SRPT) is currently trading around $21.17, a far cry from its 52-week highs above $120. Honestly, it’s been a brutal year for long-term holders, with the stock down roughly 82% over the last twelve months.
But why is everyone talking about it today?
✨ Don't miss: M\&T Bank Stock Price: Why This Regional Giant is Defying the 2026 Narrative
It’s not just the price drop. It’s the tension between a "failed" blockbuster drug and a pipeline that might just save the company. On January 17, 2026, the sentiment is split right down the middle. Some analysts are shouting "Sell" while others think this is the ultimate fire sale.
The Elevidys Drama: Is It Really a "Bust"?
The biggest thing driving SRPT news today live is the performance of Elevidys, their flagship gene therapy for Duchenne muscular dystrophy (DMD).
A few days ago, Sarepta dropped their preliminary 2025 results at the J.P. Morgan Healthcare Conference, and the market hated them. They reported $1.86 billion in total revenue for 2025, but Elevidys only pulled in $110.4 million in the fourth quarter.
Why does that matter?
Because it’s below the $500 million yearly "floor" guidance the company had previously set. CEO Doug Ingram blamed a nasty flu season and the rescheduling of six patient infusions into 2026. Skeptics, like those at H.C. Wainwright, aren't buying it. They just reiterated a Sell rating with a target price of—get this—$5.00. They’re worried that Elevidys is seeing a "steepening decline trajectory" rather than a temporary hiccup.
Safety Scares and Regulatory Hurdles
You can't talk about Sarepta without talking about safety. In 2025, two non-ambulatory patients died from acute liver failure after receiving treatment. This led to a temporary pause for certain patient segments. While shipments have resumed for ambulatory patients (those who can still walk), the company is still navigating a "risk-mitigation approach" for the more vulnerable non-ambulatory group.
Then there’s the ESSENCE trial. In November, two of Sarepta's other drugs, Amondys 45 and Vyondys 53, failed their confirmatory studies. They didn't show a statistically significant improvement in motor function compared to a placebo.
Despite this, Sarepta is still pushing for full FDA approval based on "real-world evidence." It’s a gutsy move. They have a meeting with the FDA scheduled for February or March 2026. If the FDA plays ball, analysts at Jefferies think the stock could jump 25% overnight. If not? Well, it’s going to be a long spring.
The siRNA Pipeline: The Secret Weapon?
So, if Elevidys is struggling and the PMO drugs (the exon-skipping ones) are facing regulatory heat, why is anyone still holding this stock?
The answer is siRNA.
🔗 Read more: Greg Adler Undercover Boss: What Really Happened at 4 Wheel Parts
Sarepta is pivoting hard toward its next-generation siRNA platform. They just submitted a clinical trial application for SRP-1005, a treatment for Huntington's Disease, in New Zealand. They expect to start human trials in Q2 2026.
- SRP-1001: Targeting facioscapulohumeral muscular dystrophy (FSHD).
- SRP-1003: Targeting myotonic dystrophy type 1 (DM1).
- Data Catalyst: We’re expecting Phase I/II data for these in Q1 2026.
Jefferies believes these assets alone could represent $1 billion market opportunities each. For a company with a market cap currently sitting around $2.2 billion, that’s a massive potential needle-mover.
What Real Investors Are Doing Right Now
If you look at the SRPT news today live feeds, the "Hold" rating is the consensus. Out of 30 analysts, 9 say Buy, 15 say Hold, and 6 say Sell.
It’s the classic biotech dilemma.
The company has about $953.8 million in cash. That gives them a decent runway to get through 2026 without needing an immediate, desperate capital raise. But with short interest sitting at nearly 20%, a lot of people are betting on more pain.
👉 See also: Eaton Corporation Cooper Industries: How This $11.8 Billion Power Play Changed the Grid Forever
Honestly, it feels like the market is waiting for one thing: the February FDA meeting. That’s the "make or break" moment for the current portfolio. If the FDA allows Amondys and Vyondys to stay on the market despite the trial miss, the narrative changes from "failing biotech" to "resilient survivor."
Actionable Steps for Tracking SRPT
If you're trying to play this or just want to stay informed, don't just watch the price. Watch these specific triggers:
- Watch the Q1 siRNA Data: If SRP-1001 or SRP-1003 show strong protein knockdown without safety signals, the "pivot" story becomes real.
- Monitor the FDA Calendar: The late February/early March meeting regarding the ESSENCE trial results is the biggest binary event on the horizon.
- Track Elevidys Infusion Rescheduling: Keep an eye on the Q1 2026 earnings report (usually in May) to see if those "delayed" Q4 infusions actually happened. If they didn't, the flu season excuse was probably a cover for slowing demand.
- Check Short Interest: If short interest starts to drop significantly before the FDA meeting, it might signal that the "big money" is getting nervous about a surprise positive ruling.
Basically, Sarepta is a high-stakes poker game right now. The company is betting its future on a pivot to siRNA while trying to keep its DMD franchise from crumbling under regulatory and safety pressure. For those following SRPT news today live, the next 60 days will likely define the company’s trajectory for the rest of the decade.